Differentiating T-Cell Engager Use Vs Standard Therapy in Multiple Myeloma
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Related Articles
Podcasts
CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
Novel Cancer Vaccine Combo Therapy Numerically Improves PFS in Melanoma
The novel cancer vaccine plus pembrolizumab missed statistical significance, though it generated a clinically meaningful improvement, in advanced melanoma.
Podcasts
CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
FDA Approves NGS-Based Companion Diagnostic for Zongertinib in NSCLC
The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.
Podcasts
CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
Alpelisib Combo Does Not Extend PFS in High-Grade Serous Ovarian Cancer
Additional research on novel targeted therapies may be necessary to address the unmet needs in this high-grade serous ovarian cancer population.
Leveraging Networks to Deliver Novel Therapies to Community Populations
The expertise of START’s network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types
The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.
Enfortumab Vedotin/Pembrolizumab Improved Survival Vs Surgery in MIBC
Patients with cisplatin-ineligible bladder cancer who received enfortumab vedotin plus pembrolizumab and surgery had prolonged survival vs those who received surgery alone.
Data Show Disparities in HMA Use Among Myelodysplastic Syndrome Populations
Findings demonstrate a need to move beyond disease-related factors to address disparities in HMA treatment patterns among those with MDS.